Navigation Links
Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172
Date:6/4/2008

at our website at http://www.nuvelo.com or by phoning 650-517-8000.

This press release contains "forward-looking statements," which include statements regarding the timing, progress and anticipated completion of Nuvelo's clinical stage and research programs, the anticipated availability of top-line data, projected operating expenses and cash usage and the potential benefits that patients may experience from the use of our clinical stage compounds, which statements are hereby identified as "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on our management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, uncertainties relating to drug discovery and the regulatory approval process; clinical development processes; enrollment rates for patients in our clinical trials; changes in relationships with strategic partners and dependence upon strategic partners for the performance of critical activities under collaborative agreements; and the impact of competitive products and technological changes. These and other factors are identified and described in more detail in Nuvelo's filings with the SEC, including without limitation Nuvelo's quarterly report on Form 10-Q for the quarter ended March 31, 2008 and subsequent filings. We disclaim any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE Nuvelo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172
2. Nuvelo Announces Preclinical Data for NU206 Demonstrating Potent Therapeutic Activity in Oral Mucositis Models
3. Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
4. Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172
5. Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke
6. Nuvelo Announces Alfimeprase SONOMA-2 Catheter Occlusion Data Presentation Webcast and Conference Call
7. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
8. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
9. Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
10. Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors
11. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Calif., Dec. 14 Alexza Pharmaceuticals, Inc. (Nasdaq: ... its New Drug Application (NDA) for Staccato® loxapine (AZ-004) ... AZ-004 is an inhalation product candidate being developed for ... or bipolar disorder. The IND for Staccato ... 2005. ,, "AZ-004 has delivered a predictable and consistent ...
(Date:12/14/2009)... Medical Corp., a majority-owned subsidiary of Speedus Corp. ... Siemens Corporate Research (NYSE: SI ) ... award-winning Zargis Cardioscan(TM) system on Amazon.com, America,s largest ... electronic stethoscope were jointly named Popular Science ... Year." Cardioscan is the world,s first FDA-cleared ...
(Date:12/14/2009)... health advocates hope that U.S. FDA will make ... A (BPA), a synthetic sex hormone linked to ... in time for Christmas. ,, Sarah Janssen ... Natural Resources Defense Council : "Just as you ... must rely on the advice of scientific experts. ...
Breaking Medicine Technology:Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 2Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 3Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 4Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 5Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 6Zargis Cardioscan 'The Intelligent Stethoscope' Now Available on Amazon.com 2Toxic Chemical bisphenol A Still Not Banned By FDA; Schumer, Gillibrand Call for Ban; Govt Official Warns Public 2Research Scientist Reports On Time Tested Solution To Current Medical Crisis 52724 1Research Scientist Reports On Time Tested Solution To Current Medical Crisis 52724 2Research Scientist Reports On Time Tested Solution To Current Medical Crisis 52724 3Research Scientist Reports On Time Tested Solution To Current Medical Crisis 52724 4Mylan Reiterates and Stands Behind Its 48 Year Commitment and Track Record of Quality 52720 1Common allergy drug reduces obesity and diabetes in mice 9359 1Common allergy drug reduces obesity and diabetes in mice 9359 2Common allergy drug reduces obesity and diabetes in mice 9359 3Common allergy drug reduces obesity and diabetes in mice 9359 4
... statement,by Andrea Kavanagh, Director of the Pure Salmon Campaign, ... a study tomorrow that,shows sea lice from open net ... fish stocks., "This study confirms what we have ... on wild salmon populations. If outbreaks of these,parasites are ...
... Natural Compound Responsible for ... Antioxidant and Anti-adhesion Benefits, CARVER, Mass., Dec. 13 ... showing that 1 oz. (or a 1/4,cup) of Decas Sweetened ... 8-ounce glass of cranberry juice,cocktail. Found abundantly in cranberries, proanthocyanidins ...
Other Medicine Technology:Research Shows Decas Sweetened Dried Cranberries Pack Twice the Proanthocyanidin Punch as Cranberry Juice Cocktail 2
(Date:12/14/2009)... some protection, study finds, , , MONDAY, Dec. 14 (HealthDay ... start their morning without a cup or two of ... of developing type 2 diabetes. , That,s the ... more coffee you drink, the lower your risk of ... 7 percent reduction in the risk of diabetes, the ...
(Date:12/14/2009)... and obesity are linked to an increased risk of ... glargine (a synthetic insulin preparation marketed under the trade ... of certain cancers than other insulins or oral glucose ... control for important factors such as obesity that may ... hand, a large randomized trial designed to examine another ...
(Date:12/14/2009)... lead to better treatments for asthma, COPD, researchers say ... identified five genetic variants that influence lung function, a ... lung diseases. , The international team of researchers compared ... 2.5 million sites across the human genome in more ... team to the five common genetic variants associated with ...
(Date:12/14/2009)... and smoking, but concerns about prescription abuse, , ... teenagers are using methamphetamine, but reductions in marijuana ... remains high, U.S. health officials report. , In ... the hallucinogenic salvia leaf and the prescription medication ... hyperactivity disorder (ADHD), appear to be gaining a ...
(Date:12/14/2009)... Nations Foundation’s Nothing But Nets tipped off a promotion--Send a Net. ... bed nets to refugees in 11 African countries. The effort is ... January 31, 2010. , ... New York, ... (NBA) and the United Nations Foundation’s Nothing But Nets tipped off ...
Breaking Medicine News(10 mins):Health News:Coffee, Tea Might Stave Off Diabetes 2Health News:Coffee, Tea Might Stave Off Diabetes 3Health News:UNC scientists coordinate study of link between insulin use and cancer in people with diabetes 2Health News:Marijuana Use No Longer Dropping Among U.S. Teens 2Health News:Marijuana Use No Longer Dropping Among U.S. Teens 3Health News:Marijuana Use No Longer Dropping Among U.S. Teens 4Health News:NBA Cares and United Nations Foundation Partner to Launch Send A Net. Save A Life. See A Game. Presented By HP 2Health News:NBA Cares and United Nations Foundation Partner to Launch Send A Net. Save A Life. See A Game. Presented By HP 3Health News:NBA Cares and United Nations Foundation Partner to Launch Send A Net. Save A Life. See A Game. Presented By HP 4
... identified as primary driver of increased costsINDIANAPOLIS, May ... Knowledge today released a report detailing the primary ... insurance premiums, dispelling the notion that insurer profits ... report, titled "What,s Really Driving the Increase in ...
... Launch www.aftertheinjury.org to Help Parents and Kids ... is the unfortunate nickname for summertime in the nation,s ... an estimated 3 million children under the age of ... injuries. Among the most common injuries are motor vehicle ...
... to Launch Three-Year Initiative to Improve Infection Control in ... Amgen (Nasdaq: AMGN ) today announced the ... that the vast majority of oncologists and infectious disease ... infection may have on treatment outcomes in chemotherapy patients, ...
... Nuvilex, Inc. (OTC Bulletin Board: NVLX), an ... the world,s first permanent tattoo ink designed to be ... of a June 1st article in Time Magazine. ... on Infinitink, a product developed to address tattoo regret ...
... Supplier Award for the Second Consecutive YearPRINCETON, N.J., ... CVD ) today announced that its clinical pharmacology ... its commitment to helping Lilly meet its corporate ... was recognized for outstanding customer service for its ...
... VEGAS, May 27 Body shaping will be one of ... Las Vegas and Eleme Medical, a premier body shaping company, ... procedures, SmoothShapes (R) and SmoothLipo (TM) . The ... with leading experts and Jeana Keough, SmoothShapes patient and star ...
Other Medicine News:Health News:WellPoint Institute of Health Care Knowledge Releases Report on Health Care Costs 2Health News:WellPoint Institute of Health Care Knowledge Releases Report on Health Care Costs 3Health News:Summertime or 'Trauma Season?' - Increase in Outdoor Activities Spurs Higher Risk for Child Injury 2Health News:Summertime or 'Trauma Season?' - Increase in Outdoor Activities Spurs Higher Risk for Child Injury 3Health News:New Survey Highlights Growing Concern About Risk of Infection in Cancer Patients and Emerging Antibiotic Resistance 2Health News:New Survey Highlights Growing Concern About Risk of Infection in Cancer Patients and Emerging Antibiotic Resistance 3Health News:New Survey Highlights Growing Concern About Risk of Infection in Cancer Patients and Emerging Antibiotic Resistance 4Health News:New Survey Highlights Growing Concern About Risk of Infection in Cancer Patients and Emerging Antibiotic Resistance 5Health News:New Survey Highlights Growing Concern About Risk of Infection in Cancer Patients and Emerging Antibiotic Resistance 6Health News:Time Magazine Reports on Infinitink Tattoo Ink From Nuvilex 2Health News:Time Magazine Reports on Infinitink Tattoo Ink From Nuvilex 3Health News:Covance Recognized for Outstanding Customer Service by Eli Lilly and Company 2Health News:Body Shaping Gets the Spotlight with Industry Experts and Celebrity Guest to Showcase SmoothShapes(R) and SmoothLipo(TM) Systems at THE Aesthetic Show in Las Vegas 2Health News:Body Shaping Gets the Spotlight with Industry Experts and Celebrity Guest to Showcase SmoothShapes(R) and SmoothLipo(TM) Systems at THE Aesthetic Show in Las Vegas 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: